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The objective of this study was to determine the extent of aﬂatoxin M1 (AFM1) and ochratoxin A (OTA)
contamination in human breast milk in the city of Ribeirão Preto, São Paulo State, Brazil. During 2012, 100
samples of human milk were collected at the local Human Milk Bank. The method comprised, immunoafﬁnity column puriﬁcation and isolation, liquid chromatography separation and ﬂuorescence detection. The average percentage recoveries of AFM1 and OTA spiked at 20 and 50 ng/L in control human milk
were 78.1  11.7% and 73.7  9.6%, respectively. The average relative standard deviations of AFM1 and
OTA spiked at the same levels were 11.7 and 9.6% respectively. The limits of detection was 0.3 ng/L for
AFM1 and OTA. The limit of determination was 0.8 ng/L for both mycotoxins. This method was used to
analyze 100 human milk samples, of which, two samples were found to contain AFM1 at level greater
than 0.3 ng/L. OTA was detected in 66 samples (66%), wherein 32 were above the limit of detection and
34 were in the range of from 0.8 to 21 ng/L. Results of our study indicate that breast-fed Brazilian infants
had only an insigniﬁcant exposure to AFM1 and OTA.
Ó 2013 Elsevier Ltd. All rights reserved.

Keywords:
Human milk
Aﬂatoxin M1
Ochratoxin A

1. Introduction
Breast milk provides human infants with indisputable shortterm health beneﬁts and is widely acknowledged as the most
complete form of nutrition for infants, conferring a range of beneﬁts for infants’ health, growth, immunity and development
(Healthy People 2010, Centers for Disease Control and Prevention,
Atlanta, Georgia, USA). The long-term consequences of breast
feeding are more difﬁcult to assess, but there are compelling
epidemiological data which suggest that breast feeding may protect
babies from developing allergies and may result in a lower incidence of obesity in teens and adults (Rautava & Walker, 2009).
Human milk may be a lifesaving therapy for infants and young
children with unusual medical conditions. Donor milk has been
used successfully treat a number of medical conditions in infants
(Tully, Lockhart-Borman, & Updegrove, 2004).
Mycotoxins, such as aﬂatoxins and ochratoxin A (OTA), are
natural toxins produced as secondary metabolites by moulds.
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When lactating mammals consume aﬂatoxin B1 (AFB1) contaminated feed or food, AFB1 is metabolized to form the monohydroxy
derivative, AFM1, which may be expressed in milk.
The results of a study in which male Fischer rats were separately
given AFM1 and AFB1 by stomach tube indicated that the AFM1 hydroxylated derivative has a much lower carcinogenic potency than
does the parent substance (Wogan & Paglialunga, 1974). Another
study also reported that AFM1 was found to be a weak hepatic
carcinogen compared to AFB1 (Cullen, Ruebner, Hsieh, Hyde, &
Hsieh, 1987). Although AFM1 in milk is less hazardous, by far, than
the parent compound, a limit of 0.5 parts per billion is applied in the
United States and in many other countries, largely because milk
tends to constitute a large part of the diet of infants and children.
OTA can also be found in milk. It is a kidney toxin and is carcinogenic in rats and mice and suspected as being the cause of Balkan
endemic nephropathy, a disease reported to occur in some individuals in Yugoslavia, Bulgaria, and Romania. OTA has the longest
half-life for its elimination of any of the mycotoxins examined. The
IARC (1993) has classiﬁed ochratoxin A as a possible human
carcinogen (category 2B).
Hassan et al. (2006) studied OTA as an environmental risk that
caused renal injury in breast-fed Egyptian infants and concluded
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Fig. 1. LC chromatograms of (a) blank, (b) human milk samples naturally contaminated with AFM1, retention time, 3.8 min and (c) OTA, retention time, 10.4 min.

that there was a signiﬁcant correlation between a higher OTA level
in infants’ sera and the degree of microalbuminuria.
Biasucci et al. (2011) study the presence of OTA in cord serum and
human milk, a positive relationship between serum OTA and ratio
serum/milk OTA was found. The intake of OTA had no effect on the
cord blood creatinine level. Muñoz et al. (2010) determined OTA and
its metabolite ochratoxin alpha in milk and blood from lactating
women, there was no evidence for conjugates of OTA and the data on
OTA in breast milk and levels reported in blood from women in Chile
are indicative of an efﬁcient lactational transfer of the mycotoxin.

There are many reports of AFM1 and or OTA contamination in
human milk, in Iran (Sadeghi et al., 2009), Brazil (Navas, Sabino, &
Rodriguez-Amaya, 2005), Turkey (Gurbay, Sabuncuoglu, et al.,
2010; Gurbay, Girgin, et al., 2010), Italy (Galvano et al., 2008),
Egypt (Polychronaki et al., 2006), Jordan (Omar, 2012) and Germany
(Muñoz, Wollin, Kalhoff, & Degen, 2013).
The goal of our study was to examine the levels of AFM1 and OTA
in the city of Ribeirão Preto, São Paulo State, Brazil. This report
updated data reported 2005 about levels of contamination of these
two mycotoxins in human milk samples collected in the Human
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Milk Bank “Enfermeira Anália Ribeiro Heck”, of Hospital das Clinicas e USP, in Ribeirão Preto City, São Paulo State. The Human Milk
Bank was founded in 1976, provide milk from screened donors that
has been used successfully treat a number of medical conditions in
infants in the region of Ribeirão Preto City. The human milk is
analyzed, pasteurized and storage in freezer at 20  C, until be
distributed for the hospital that needs it. The Bank has about 35
donors/week and provides milk for about 40 infants/day.

Table 1
Recovery of aﬂatoxin M1 and ochratoxin A in human milk (n ¼ 3).
Mycotoxin

Mycotoxin spiked, ng/L

A total of 100 human milk samples were collected from the
Human Milk Bank of Hospital das Clínicas e USP, Ribeirão Preto
City, São Paulo State, Brazil from June 2011 to Aug 2012. Volunteers
gave informed written consent to participate in this study, which
was approved by the Ethics Committee of Instituto Adolfo Lutz.
2.2. Chemicals and supplies
The chemicals and supplies used in the study were: AFM1
standard (A6428, Sigma Chemical Company, St Louis, MO, USA);
methanol and acetonitrile, LC grade (EM Science, Gibbstown, NJ,
USA); immunoafﬁnity column (IAC), wideboreAﬂaOchra (Vicam,
Watertown, MA, USA).
A stock solution of AFM1 was prepared in acetonitrile and OTA
was prepared in methanol; the concentrations of the solutions
were determined according to AOAC International Ofﬁcial Methods
986.16, 971.22 and 970.44 (AOAC, 2010). AFM1 and OTA working
solutions were prepared by diluting appropriate portions of the
stock solutions of the mycotoxins with the respective mobile phase
to give the following concentrations: 2.5; 5; 10; 20; and 40 ng/L. For
spiking solutions, appropriate portions of the stock solutions were
diluted with methanol to give concentrations of 107 mg/L for OTA
and 100 mg/L for AFM1.
2.3. Apparatus
Equipment used in this study included spectrophotometer
(Hitachi, Tokyo, Japan); vortex mixer (Fanem, São Paulo, Brazil);
centrifuge (Fanem, São Paulo, Brazil); and column manifold
(Supelco, Bellefonte, PA, USA).
2.4. Analytical procedure
2.4.1. Sample preparation and extraction
2.4.1.1. Human milk samples. The liquid samples were shaken
manually for 5 min before being opened to ensure sample homogeneity. Test samples were centrifuged for 20 min; the top layer
was aspirated, and 50 mL of the lower layer was diluted with 20 mL
hot water (80  C) and saved for IAC puriﬁcation and toxin isolation.
2.4.1.2. Human milk for recovery study. An appropriate amount of
AFM1 and OTA was added to 50 mL control milk samples (containing AFM1 and OTA < 0.3 ng/L) to obtain AFM1 and OTA levels 20
and 50 ng/L, in triplicate. Test portions were diluted in 20 mL hot
water (80  C) and saved for IAC analysis.
2.4.2. Immunoafﬁnity column puriﬁcation and isolation
Test solutions from Section 2.4.1 were passed through an IAC
secured on a column manifold. The column was then washed twice
with 10 mL water. AFM1 and OTA were eluted with methanol. The
eluate was evaporated to dryness and the residue was reconstituted
in 0.5 mL LC mobile phase.

Means

SD

RSDr

AFM1

50
20
Means

73.7
82.6
78.1

5.6
15.9
11.7

7.7
19.2
13.5

OTA

50
20
Means

70.6
76.9
73.7

6.9
12.3
9.6

9.8
16.0
12.9

2. Material and methods
2.1. Materials

Recovery, %

S.D. ¼ standard deviation, RSDr ¼ relative standard deviation.

2.4.3. Liquid chromatography
LC system included a LC pump (Shimadzu Instruments, Kyoto,
Japan) with a ﬂuorescence detector, a Rheodyne L.P. injector
with a 50 mL loop (Rheodyne, Cotati, CA, USA) and a Shim-pack
CLC-ODS (M), 4.6  250 mm, 5 mm column (Shimadzu, Kyoto,
Japan). Mobile phase was a mixture of acetonitrileewatereacetic
acid (50 þ 50 þ 1 v þ v), isocratic mode with a ﬂow rate of
0.8 mL/min. The ﬂuorescence detector was programmed from
0 to 5 min an excitation wavelength of 360 nm, emission 430 nm
for AFM1, and for 5e12 min 333 nm and 443 nm for OTA. The
injection volume was 50 mL.

3. Results and discussion
Fig. 1 shows LC chromatograms of blank (a) and human milk
samples naturally contaminated with AFM1 (b) and OTA (c). The
control milk sample shows no peak near the AFM1 and OTA
retention time (3.8 min for AFM1 and 10.5 min for OTA). This indicates that the method provides test extracts that are free of interferences for LC analysis.
A linear calibration curve (coefﬁcient of correlation, r2 ¼ 0.999)
for AFM1 with linear range from 2.5 to 40 ng/L was obtained using
the least-squares regression equation: y ¼ 21036x. OTA with the
same linear range the linearity r2 was 0.994 and y ¼ 19,283x.
Table 1 summarizes the results of the recovery study for AFM1
and OTA added to human milk samples. The mean recovery and
relative standard deviation (RSDr) at added levels of 20 and 50 ng/L
were 78.1 11.7% for AFM1 and 73.7  9.6% for OTA. The limit of
detection (LOD) for both mycotoxins was 0.3 ng/L, and was determined by using the average value of blank samples plus 2 standard
deviations.
The limit of quantiﬁcation for both mycotoxins was 0.8 ng/L
(approximately 3 times the LOD). The results indicate that the
method is adequate for the determination of AFM1 and OTA in
human milk at low levels.
Table 2 shows the results for OTA in human milk samples. In this
study 100 human milk samples were analyzed and OTA was
detected in 66 samples; among these samples, 32 samples contained OTA above LOD and 34 samples contained OTA ranging from
1 to 21 ng/L, with an average level of 4 ng/L. The occurrence and

Table 2
Ochratoxin A contamination in human milk (n ¼ 100).
No. of samples

Range, ng/L

34
32
29
2
2
1

<0.3
0.3e<0.8
0.8e5
6e10
11e15
21
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incidence of AFM1 were much less than for OTA, only 2 samples
were contaminated with AFM1 at 0.3 and 0.8 ng/L. One of these 2
samples was also contaminated with OTA at 1.1 ng/L. The levels
were much lower than the maximum legal limits in baby food in
Brazil, 2 mg/kg for OTA and 0.5 ng/kg for AFM1, (Ministério da
Saúde, 2011).
In 2005 Navas et al. (2005) analyzed for AFM1 and OTA in 50
samples from a Human Milk Bank in São Paulo City, and found only
one was contaminated with AFM1, at 20 ng/L and two with OTA, at
10 and 20 ng/L. Navas et al. (2005) also indicated that although the
incidence and occurrence observed in her study were low, but she
recommended that the study be extended to other milk banks of
the city of São Paulo. Our human milk study was a follow-up to this
recommendation although in a different city of São Paulo State,
Ribeirão Preto-SP is locate about 400 km far from São Paulo City, it
is a agricultural region.
Comparing the result of AFM1 concentration in human milk
from this work with our previous study in ﬂuid cow milk samples,
the concentrations of AFM1 in cow milk ranged from 8 to 437 ng/L,
and 30 of 47 samples were contaminated with the toxin (>1 ng/L)
(Iha, Barbosa, Okada, & Trucksess, 2013). The advantages of breast
feeding are many. In addition to being nutritious, human milk may
contain less mycotoxins and their metabolites; however, if breast
feeding is not an option, then it might be safer to feed infants with
powdered infant formula. None of the 7 powdered infant formulae
designated for babies aged from 0 to 6 months were found to be
contaminated with AFM1.
In Egypt, Polychronaki et al. (2006) analyzed 388 samples and
found 36% contaminated with AFM1, with a median concentration
of 13.5 ng/L. Galvano et al. (2008) collected 82 human milk samples
from an Italian hospital and detected AFM1 in 4 samples, 7e140 ng/
L. Occurrence and levels of AFM1 in Brazilian human milk samples
were signiﬁcantly lower than those from other countries. Sadeghi
et al. (2009) reported that in Tehran, Iran, 157 of 160 human milk
samples were determined to be contaminated with AFM1 at concentrations of 0.3e26.7 ng/kg. Gurbay, Sabuncuoglu, et al. (2010)
studied 75 human milk samples from Ankara, Turkey, and found
AFM1 in all samples at concentration levels of 60.9e300.0 ng/L.
There were also reports of ﬁnding OTA in human milk in several
countries. Galvano et al. (2008) analyzed 82 human milk samples
collected from a hospital in Italy and found OTA in 61% of the
samples with OTA levels ranged from 5 to 405 ng/L. Gurbay, Girgin,
et al. (2010) found 100% OTA contamination with levels ranging
from 620 to 13,111 ng/L in 75 human milk samples collected in
Ankara, Turkey. Muñoz et al. (2013) obtained 90 milk samples from
mothers in Germany and found more than 50% of the samples
contained OTA > 10 ng/L.
In our study we found 66% of the 100 samples contained
OTA > 0.3 ng/L with an average of 4 ng/L.
In conclusion, the levels of AFM1 and OTA in all human milk
collected from the city of Ribeirão Preto, São Paulo State, Brazil.
During 2012 was very low, much lower than the current Brazil
regulatory limits. Therefore, the infant health risk associated with
the two mycotoxins in human milk was very low in this area. We
therefore did not estimate the exposure assessment. In addition, in
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Brazil, breast feeding could result in lower mycotoxin exposure
than cow milk feeding.
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